![Resistance to Molecular Therapies for Hepatocellular Carcinoma](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
![Resistance to Molecular Therapies for Hepatocellular Carcinoma](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
Resistance to Molecular Therapies for Hepatocellular Carcinoma
-
- €119.99
-
- €119.99
Publisher Description
This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.
Other Books in This Series
Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
2018
Resistance to Targeted Therapies in Breast Cancer
2017
Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
2018
Resistance to Ibritumomab in Lymphoma
2018
Cancer Stem Cell Resistance to Targeted Therapy
2019
Current Applications for Overcoming Resistance to Targeted Therapies
2019